



February 6, 2018

1102817

Mr. George Kaminsky  
Director, British Columbia  
Canadian Pulmonary Fibrosis Foundation  
107 - 3750 Edgemont Blvd  
North Vancouver BC V7R 2P8

Dear Mr. Kaminsky:

Thank you for your letter of January 19, 2018, regarding your request for a meeting to discuss PharmaCare Coverage of nintedanib (Ofev®) and pirfenidone (Esbriet®) for treatment of Idiopathic Pulmonary Fibrosis (IPF).

I appreciate your interest in this matter. Effective February 6, 2018, PharmaCare listed both pirfenidone (Esbriet) and nintedanib (Ofev) as Limited Coverage benefits for treatment of IPF for patients who fulfil certain clinical criteria. As a result, given that this issue has moved forward I do not feel that a meeting would be productive at this time.

Thank you for the opportunity to respond.

Sincerely,

A handwritten signature in blue ink, appearing to read "M Moneo". The signature is fluid and cursive.

Mitch Moneo  
Assistant Deputy Minister  
Pharmaceutical Services Division